Español
In October 2025, Sylentis participated in the annual conference of the Oligonucleotide Therapeutics Society (OTS) held in Budapest, one of the most important international meetings in the field of RNA-based therapies and therapeutic oligonucleotides.
During the event, Pablo Lores Lareo, Business Development Manager at Sylentis, shared the company’s vision of its role in the global biotechnology landscape and how the Syoligo project, part of the European IPCEI Med4Cure programme, is strengthening its international competitiveness as a CDMO specialising in therapeutic oligonucleotides.
What role does Sylentis play in the global landscape of oligonucleotide-based therapies, and what opportunities does its participation in OTS 2025 open up?
Sylentis has been a pioneer in the development of oligonucleotide-based therapies, particularly in the field of RNA interference. This track record has served as the basis for building a specialised CDMO offering that combines GMP manufacturing capabilities with deep scientific and regulatory expertise. Participation in OTS 2025 represents a strategic opportunity to showcase our technical capabilities to potential partners, access the latest innovations in the field, and strengthen our position in the RNA therapeutics ecosystem.
From a business development perspective, how can the SYOLIGO project strengthen Sylentis’ competitiveness in the international market?
The SYOLIGO project, part of the European IPCEI Med4Cure programme, is a strategic commitment that reinforces Sylentis’ position as a European leader in the sustainable and scalable production of therapeutic oligonucleotides. Thanks to this initiative, we have made a significant leap forward in industrial capacity, enabling us to expand our offering as a CDMO and open up new avenues of collaboration with European players. From a business development perspective, SYOLIGO allows us to compete in new markets, attract international customers and consolidate our presence as a preferred partner in advanced therapy projects.
What kind of collaborations are expected to be promoted during OTS 2025 to accelerate innovation in therapeutic oligonucleotides?
OTS 2025 will bring together more than 900 experts from 25 countries, including academic and industry leaders, in what is considered the most important scientific conference in the sector. This is where ideas are presented that, in a few years, will give rise to the next clinical candidates. Sylentis attends with the aim of supporting researchers and companies in the process of turning a treatment into a medicine, offering our technical and regulatory knowledge, as well as our experience in the development of RNA therapies. The conference provides an ideal environment for establishing new collaborations and attracting new customers.
Participation in OTS Budapest 2025 has provided Sylentis with a strategic meeting point with the international scientific and business community, reinforcing its position as one of the European leaders in the development and manufacture of RNA therapies.
As Pablo Lores Lareo pointed out, the Syoligo project has enabled the company to make a significant leap forward in industrial capacity and international collaboration, expanding its offering as a CDMO and contributing to the development of a stronger, more sustainable and competitive biotechnology sector in Europe.
With this experience, Sylentis reaffirms its commitment to innovation, technology transfer and the manufacture of oligonucleotides. a9> and manufacturing of oligonucleotides under GMP standards, moving towards a future in which European biotechnology plays a leading role a22> plays a leading role in precision medicine.
